Epstein Secrets

From: jeffrey E. <[email protected]> Sent: Monday, August 8, 2016 8:59 PM To: Ens, Amanda; Richard Kahn Subject: Re: Preferreds, thoughts on fixed income, mandatory converts lets buy 1 m each =div class="gmail_quote">On Mon, Aug 8, 201

to TEVA was already built into most analyst models, the =NDA sale was not. Revenue thus looks 3 EFTA_R1_01555604 EFTA02454073 in line. Botox and Restasis, two impo=tant products, are still growing at 16% and 21% respectively. AGN has an aggressive buyback program, target=ng $5bn this year and they sho

From: jeffrey E. <[email protected]> Sent: Tuesday, August 9, 2016 2:23 PM To: Ens, Amanda Subject: Re: Preferreds, thoughts on fixed income, mandatory converts When will yours open?? On Tuesday, 9 August 2016,=Ens, Amanda < III /a» wro

s to TEVA. While=the generics sale to TEVA was already built into most analyst models, the =NDA sale was not. Revenue thus looks in line. Botox and Restasis, two impo=tant products, are still growing at 16% and 21% respectively. AGN has an aggressive buyback program, target=ng $5bn this year and they sho

global connections'" From: Jeffrey E. [mailto:[email protected] <mailto:[email protected]> Sent: Monday, August 08, 2016 4:14 PM To: Ens, Amanda Subject: Re: Preferreds, thoughts on fixed income, mandatory converts send more detail of the bond On Mon, Aug 8, 2016 at 2:26 PM, Ens, Amanda <

s to TEVA. While the generics sale to TEVA was already built into most analyst models, the ANDA sale was not. Revenue thus looks in line. Botox and Restasis, two important products, are still growing at 16% and 21% respectively. AGN has an aggressive buyback program, targeting $5bn this year and they sho

From: Jeffrey E. [mailto:[email protected] <mailto:[email protected]> Sent: Monday, August 08, 2016 4:14 PM To: Ens, Amanda Subject: Re: Preferreds, thoughts on fixed income, mandatory converts send more detail of the bond On Mon, Aug 8, 2016 at 2:26 PM, Ens, Amanda d »

s to TEVA. While the generics sale to TEVA was already built into most analyst models, the ANDA sale was not. Revenue thus looks in line. Botox and Restasis, two important products, are still growing at 16% and 21% respectively. AGN has an aggressive buyback program, targeting $5bn this year and they sho

<1=> <1=> </=> From: jeffrey =. (mailto:[email protected] <mailto:[email protected]> I Sent: Monday, August 08, 2016 4:14 PM To: Ens, Amanda Subject: Re: Preferreds, thoughts on fixed income, mandatory convert= send more detail of the bond On Mon, Aug 8, 2016 at 2:26 PM, Ens, Amanda <

s to TEVA. While=the generics sale to TEVA was already built into most analyst models, the =NDA sale was not. Revenue thus looks in line. Botox and Restasis, two impo=tant products, are still growing at 16% and 21% respectively. AGN has an aggressive buyback program, target=ng $5bn this year and they sho

From: Jeffrey E. [mailto:[email protected] <mailto:[email protected]> Sent: Monday, August 08, 2016 4:14 PM To: Ens, Amanda Subject: Re: Preferreds, thoughts on fixed income, mandatory converts send more detail of the bond On Mon, Aug 8, 2016 at 2:26 PM, Ens, Amanda <am

s to TEVA. While the generics sale to TEVA was already built into most analyst models, the ANDA sale was not. Revenue thus looks in line. Botox and Restasis, two important products, are still growing at 16% and 21% respectively. AGN has an aggressive buyback program, targeting $5bn this year and they sho